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Human rabies immunoglobulin (HRIG)
Equine rabies immunoglobulin (ERIG)
a b s t r a c t
Immediate passive immune prophylaxis as part of rabies post-exposure prophylaxis (PEP) often cannot be
provided due to limited availability of human or equine rabies immunoglobulin (HRIG and ERIG, respec-
tively). We report first clinical data from two phase I studies evaluating a monoclonal antibody cocktail
CL184 against rabies.
The studies included healthy adult subjects in the USA and India and involved two parts. First, subjects
received a single intramuscular dose of CL184 or placebo in a double blind, randomized, dose-escalation
trial. Second, open-label CL184 (20 IU/kg)was co-administeredwith rabies vaccine. Safetywas theprimary
objective and rabies virus neutralizing activity (RVNA) was investigated as efficacy parameter.
Pain at the CL184 injection site was reported by less than 40% of subjects; no fever or local induration,
redness or swelling was observed. RVNA was detectable from day 1 to day 21 after a single dose of CL184
20 or 40 IU/kg. All subjects had adequate (>0.5 IU/mL) RVNA levels from day 14 onwards when combined
with rabies vaccine. CL184 appears promising as an alternative to RIG in PEP.
© 2008 Elsevier Ltd. All rights reserved.
1. Introduction
Rabies occurs worldwide and more than 3 billion people live in
areas inwhich the disease is enzootic. Especially children are at risk
of infection. Every year about 55,000 people die from rabies, more
than 50% of these in Asia [1,2].
Once clinical symptoms develop, rabies is almost invariably
fatal [3]. However, rabies is preventable: even in case of severe
rabies exposure (category III according to World Health Organi-
zation guidelines), post-exposure prophylaxis (PEP) consisting of
thoroughwound cleansing and immediate administration of rabies
immune globulin (RIG) together with a full course of rabies vacci-
nation is highly effective [4,5].
∗ Corresponding author at: Crucell Holland BV, P.O. Box 2048, 2301 CA Leiden,
The Netherlands.
E-mail address: lex.bakker@crucell.com (A.B.H. Bakker).
The success of PEP largely depends on an educated population
and on the supply ofmodernRIGs and rabies vaccines [2]. The avail-
ability of high-quality biologicals is still low indeveloping countries
and many patients die because PEP is not administered at all or
because no RIG is administered [6,7].
The administration of RIG as soon as possible after exposure
is essential to inhibit viral spread in the interval before sufficient
immunity is developed in response to vaccination [1,3]. Currently,
human (HRIG) and equine (ERIG) immuneglobulins are used. These
plasma-derived, polyclonal products are obtained from rabies-
vaccinated human donors or horses and can only be produced
in limited amounts. Therefore, the WHO strongly encourages the
development of alternatives [1,8].
We have developed a human monoclonal antibody (mAb)
cocktail, CL184, which consists of two mAbs (CR57, human IgG1
lambda and CR4098, human IgG1 kappa). These mAbs, produced
on the PER.C6® human cell line, are directed against distinct,
non-overlapping rabies virus epitopes anddonot compete for bind-
ing to rabies glycoprotein [9,10]. CL184 has demonstrated broad
0264-410X/$ – see front matter © 2008 Elsevier Ltd. All rights reserved.
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Table 1
Demographic characteristics
RAB-M-A001 Placebo (N=11) CL184 8 IU/kg (N=12) CL184 20 IU/kg (N=11) CL184 40 IU/kg (N=12) CL184 20 IU/kg+
PCECV (N=11)
Sex (n (%)) Female 4 (36) 6 (50) 3 (27) 5 (42) 7 (64)
Male 7 (64) 6 (50) 8 (73) 7 (58) 4 (36)
Race (n (%)) Asian 0 0 1 (9) 0 1 (9)
Black 1 (9) 0 0 0 1 (9)
Caucasian 9 (82) 11 (92) 9 (82) 10 (83) 8 (73)
European/Middle Eastern 0 0 0 1 (8) 0
Hispanic 1 (9) 1 (8) 0 1 (8) 0
Mixed 0 0 1 (9) 0 1 (9)
Mean age (years) min, max 29 (19,44) 30 (19,51) 27 (20,46) 31 (19,54) 27 (19,37)
Mean BMI (kg/m2) S.D. 23.9 (2.2) 23.7 (2.1) 24.7 (2.1) 23.0 (2.5) 24.0 (2.4)
RAB-M-A002 Placebo (N=7) – CL184 20 IU/kg (N=12) CL184 40 IU/kg (N=12) CL184 20 IU/kg+
PCECV (N=12)
Sex, n (%) Female 3 (43) – 6 (50) 6 (50) 6 (50)
Male 4 (57) – 6 (50) 6 (50) 6 (50)
Race, n (%) Asian 7 (100) – 12 (100) 12 (100) 12 (100)
Mean age (years) min, max 30 (22,38) – 29 (21,37) 29 (19,39) 29 (20,39)
Mean BMI (kg/m2) S.D. 22.7 (2.8) – 21.7 (2.5) 22.7 (2.9) 24.6 (2.5)
The placebo groups were pooled. BMI: body mass index; min: minimum; max: maximum; S.D.: standard deviation; PCECV: purified chick embryo cell culture vaccine.
neutralization in vitro of a large panel of rabies street viruses from
various animal species, aswell as in vivoprotection in a Syrian ham-
ster rabies challenge model, achieving results comparable to those
obtained with HRIG [9–11].
Wehave performed twophase I studies, one in theUSA (RAB-M-
A001) and one in India (RAB-M-A002), with the primary objective
of investigating the safety and tolerability of CL184 in healthy adult
subjects.We also collected data on rabies virus neutralizing activity
(RVNA) after administration of single doses of CL184 alone or in
conjunction with rabies vaccine.
2. Methods
2.1. Subjects
Female and male healthy adult subjects (RAB-M-A001: ≥19
to ≤55 years; RAB-M-A002: ≥18 to ≤55 years) without previous
exposure to rabies vaccine were eligible. Main exclusion criteria
were pregnancy, febrile illness, known or suspected impairment
of the immune system, intake of immunosuppressive medication,
or clinically significant laboratory, cardiac, or physical examination
findings.
Written informed consent was obtained from all subjects. The
studies were approved by the local independent review boards and
were performed according to International Conference on Harmo-
nization guidelines for Good Clinical Practice (ICH-GCP) and the
Declaration of Helsinki.
2.2. Procedures
RAB-M-A001was performed in Lincoln, Nebraska, USA (Decem-
ber 2006 to May 2007); RAB-M-A002 was carried out in Mumbai,
India (April 2007 to July 2007). Both studies consisted of two parts.
Table 2
Subjects with solicited adverse events
RAB-M-A001 Placebo (N=11) CL184 8 IU/kg (N=12) CL184 20 IU/kg (N=11) CL184 40 IU/kg (N=12) CL184 20 IU/kg+
PCECV (N=11)
Local reactions
Induration 0 0 0 0 0
Pain 1 (9%) 1 (8%) 4 (36%) 3 (25%) 1 (9%)
Redness 0 0 0 0 0
Swelling 0 0 0 0 0
Systemic adverse events
Fever 0 0 0 0 0
RAB-M-A002 Placebo (N=7) – CL184 20 IU/kg (N=12) CL184 40 IU/kg (N=12) CL184 20 IU/kg+
PCECV (N=12)
Local reactions
Induration 0 – 0 0 0
Pain 0 – 2 (17%) 0 0
Redness 0 – 0 0 0
Swelling 0 – 0 0 0
Systemic adverse events
Fever 0 – 0 0 0
Data are number of subjects (%). Local reactions were assessed at the CL184/placebo injection site for 4 days after injection. Fever: body temperature≥38 ◦C. PCECV: purified
chick embryo cell culture vaccine.
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Table 3
Most frequently reported unsolicited adverse events
RAB-M-A001 Placebo (N=11) CL184 8 IU/kg (N=12) CL184 20 IU/kg (N=11) CL184 40 IU/kg (N=12) CL184 20 IU/kg+PCECV (N=11)
Subjects with ≥1 adverse event 9 (82) 11 (92) 10 (91) 9 (75) 11 (100)
Abdominal pain upper 0 0 1 (9) 0 2 (18)
AST increased 0 2 (17) 1 (9) 0 0
CK–MB increased 3 (27) 2 (17) 0 0 1 (9)
Cough 4 (36) 2 (17) 3 (27) 1 (8) 2 (18)
Dermatitis contact 0 0 2 (18) 0 0
Dizziness 1 (9) 1 (8) 1 (9) 1 (8) 2 (18)
Fatigue 1 (9) 1 (8) 0 1 (8) 4 (36)
Headache 2 (18) 6 (50) 6 (55) 2 (17) 3 (27)
Injection site bruising 1 (9) 3 (25) 1 (9) 1 (8) 4 (36)
Injection site discomforta 0 0 0 0 4 (36)
Injection site paina 0 0 0 0 2 (18)
Lymphadenopathy 1 (9) 5 (42) 3 (27) 2 (17) 0
Menstruation irregular 0 0 0 2 (17) 0
Nasal congestion 0 2 (17) 2 (18) 1 (8) 4 (36)
Neck pain 1 (9) 2 (17) 0 1 (8) 0
Pain in extremity 0 0 0 0 4 (36)
Pharyngolaryngeal pain 2 (18) 3 (25) 1 (9) 1 (8) 2 (18)
Rhinorrhoea 2 (18) 0 2 (18) 2 (17) 0
Sinus congestion 2 (18) 0 0 0 0
Vomiting 0 1 (8) 2 (18) 1 (8) 0
RAB-M-A002 Placebo (N=7) – CL184 20 IU/kg (N=12) CL184 40 IU/kg (N=12) CL184 20 IU/kg+PCECV (N=12)
Subjects with ≥1 adverse event 2 (29) – 4 (33) 8 (67) 3 (25)
CK-MB increased 0 – 0 1 (8) 2 (17)
Lipase increased 0 – 0 2 (17) 0
Vomiting 0 – 0 2 (17) 0
Data are number of subjects (%). Adverse events occurring in at least two subjects in a group are shown. PCECV: purified chick embryo cell culture vaccine.
a At the vaccine injection site.
Part 1 had a double blind, placebo-controlled, dose-escalation
design. Subjects were assigned to single doses of CL184 (8 IU/kg,
20 IU/kg, or 40 IU/kg in RAB-M-A001; 20 IU/kg or 40 IU/kg in
RAB-M-A002) or placebo in a 3:1 ratio according to a computer-
generated block randomization list. Placebo consisted of the CL184
formulation buffer with the identical excipient composition but
lacking the active ingredients CR57 and CR4098. In RAB-M-A001,
the first four subjects at each dose level were dosed at least 2h
apart; the next subjects were dosed at least 10 days later. In both
studies, day 7 data for each dosage groupwere examined to exclude
safety concerns before a higher dose was given in the next group.
Part 2 had an open-label, uncontrolled design, in which CL184
20 IU/kg was given on day 0 in a simulated PEP setting, in conjunc-
tion with purified chick embryo cell culture (PCEC) rabies vaccine
administered intramuscularly according to theEssen regimen (days
0, 3, 7, 14, 28) [12].
CL184 contained 1000 IU/mL of a 1:1 equipotent mixture of the
mAbs CR57 and CR4098. Single doses were injected into the lat-
eral thigh muscle. One millilitre of rabies vaccine (RAB-M-A001:
RabAvertTM, Lot No. 411011 potency 9.7 IU/dose and Lot No. 406011
potency7.1 IU/dose; RAB-M-A002: RabipurTM, LotNo. 1415potency
9.05 IU/dose) was injected into the deltoid muscle (contralateral to
CL184/placebo).
The subjects arrived at the clinical centre on the day before dos-
ing andwere kept under observation for 96h (RAB-M-A001, first in
human administration) or 24h (RAB-M-A002) after dosing. In both
study parts, blood samples were collected before dosing on day 0,
and on days 1, 2, 3, 7, 14, 21, 28, and 42.
Safety assessments included physical examination, electrocar-
diogram, blood pressure and heart rate monitoring, and routine
laboratory tests. Human anti-human antibodies (HAHAs) were
measured using a BIACore® assay at BioAnaLab Ltd., Oxford, UK.
Unsolicited adverse events were recorded throughout the study.
In addition, the subjects were asked if they had experienced
induration, pain, redness, or swelling at the CL184/placebo injec-
tion site and body temperature was documented for 4 days after
CL184/placebo administration (solicited adverse events).
RVNAwasmeasured with the rapid fluorescent focus inhibition
test (RFFIT) [13] at Kansas State Veterinary Diagnostic Laboratory,
Manhattan, USA.
The studies were registered as ISRCTN (ISRCTN18660493 and
ISRCTN12693237).
2.3. Statistical analysis
The primary objective of both studies was to investigate safety;
no inferential statistics were performed. Safety was analysed
descriptively for all subjects who had received CL184/placebo.
For calculation of geometricmeanRVNA, values below the lower
limit of quantitation of 0.05 IU/mLwere set to half of the limit. Data
from subjects with detectable RVNA at baseline (pre-dose) were
excluded from the RVNA analysis (three subjects in RAB-M-A001
and four subjects in RAB-M-A002).
3. Results
RAB-M-A001 included 57 subjects, of whom five did not com-
plete the study because of non-compliance or withdrawal of
consent. Of the 44 subjects enrolled in RAB-M-A002, onewaswith-
drawn before administration of placebo due to non-compliance.
RAB-M-A001 (USA) included mainly Caucasians while all subjects
participating in RAB-M-A002 (India) were Asian. Table 1 sum-
marizes demographic characteristics. Demographic characteristics
were well balanced for all groups in RAB-M-A002; in RAB-M-A001,
two CL184 dosage groups differed with respect to sex distribution.
Subjects in both studies reported only a few local reactions
(Table 2) during the 4 days after CL184 injection. Pain at the
injection site was noted by one to four subjects in each group
in RAB-M-A001 and by two subjects in the CL184 20 IU/kg group
in RAB-M-A002. There were no occurrences of induration, red-
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Fig. 1. Rabies virus neutralizing activity (RVNA). Data are geometric means and 95% confidence intervals. Values below the detection limit of 0.05 IU/mL were set to half of
the limit. Subjects with detectable RVNA at baseline were excluded from the analysis.
ness, or swelling at the injection site, and no subjects developed
fever.
In RAB-M-A001, most subjects receiving CL184 without vacci-
nation reported unsolicited adverse events (Table 3); the incidence
rates were similar to those after placebo administration and no
dose-relationship was observed. When CL184 was administered
in conjunction with rabies vaccine, all subjects reported adverse
events. A different pattern of adverse events was observed in RAB-
M-A002,where incidence rateswere low (less or equal to one-third
of subjects) in all but the CL184 40 IU/kg group (two-thirds of sub-
jects). Adverse events affecting at least two subjects in a group in
both studies were increased creatinine kinase muscle–brain isoen-
zyme (CK-MB, indicative of cardiac muscle involvement) levels
and vomiting. The elevation of CK-MB was not accompanied by
clinical signs or symptoms, and both of these events appeared to
be unrelated to CL184.
Serious adverse events were reported by two subjects
participating inRAB-M-A001, both in theCL18440 IU/kggroup.One
subject was hospitalized for mild back pain and muscle strain due
to amotor vehicle accident; the other experienced suicidal ideation
andworsening of anundisclosedpre-existing post-traumatic stress
disorder upon stopping his medications (without consulting a
physician) in order to participate in the study. Both events were
assessed by the investigator as being mild and unrelated to CL184
administration. In RAB-M-A002, one case of hepatitis E infection
was reported as a serious adverse event in a subject receiving CL184
40 IU/kg. This event was of severe intensity and was assessed as
being unrelated to treatment.
There were no discontinuations due to adverse events.
Most adverse events in both studies were of mild intensity.
Severe but non-serious events after CL184 administration were
increased CK, increased CK-MB, and increased lipase. These events
were all assessed by the investigator as being unrelated to
CL184.
Routine safety laboratory tests revealedelevationsof clinical rel-
evance inAspartate Transaminase (AST), CK-MB, or lipase in several
subjects receiving CL184 or placebo; no treatment- or dose-related
trends were observed. The other safety assessments found no indi-
cations of hepatic, cardiac, or pancreatic disorders.
Treatment-emergent CL184-specific HAHAs were not detected
in any subjects.
RVNAwas consistently detectable by RFFIT from day 1 up to day
21 after administration of CL184 20 IU/kg or 40 IU/kg, but not CL184
8 IU/kg. The dose-escalation parts of the studies showed dose-
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dependent increases in geometric mean RVNA (Fig. 1 panels A and
B). In RAB-M-A001, peak levels were reached by day 7 after admin-
istration of CL184 8 IU/kg (0.06 IU/mL) or 20 IU/kg (0.30 IU/mL) and
by day 14 after administration of CL184 40 IU/kg (0.46 IU/mL). In
RAB-M-A002, the highest levels were observed on day 3 (CL184
40 IU/kg: 0.32 IU/kg) and day 7 (CL184 20 IU/kg: 0.24 IU/kg).
When a single dose of CL184 20 IU/kg (day 0) was administered
in a simulated PEP setting together with rabies vaccination (days 0,
3, 7, 14 and 28), RVNA levelswere comparable to those after admin-
istrationofCL18420 IU/kgaloneup today3 (Fig. 1panelsCandD).A
steep increase in RVNA levels was seen from day 7 to day 14 in both
studies. The peak value was lower in RAB-M-A002 (12.38 IU/mL)
than in RAB-M-A001 (56.43 IU/mL). After day 14, RVNA levels
decreased slightly until day 42 in RAB-M-A001, but showed a slight
increase towards the end of the study in RAB-M-A002. From day
14 onwards, all subjects in both studies had RVNA levels above
0.5 IU/mL, the level considered adequate according to WHO [1].
Four out of 11 (RAB-M-A001) and three out of ten subjects (RAB-M-
A002) had RVNA levels exceeding the threshold as early as day 7.
4. Discussion
Although effective PEP regimens are established, human death
rates due to rabies infection remain unacceptably high [1]. True
PEP failures are rare, but many patients exposed to rabies do not
receive adequate medical care [7]. Improper wound cleaning or a
delayed onset of PEP put patients at risk of death. The same is true
if incomplete PEP regimens are used, which happens frequently
because of unavailability of proper quality biologicals. An Indian
survey showed that in 2003 only 2.1% of patientswith severe rabies
exposure received RIG [14]. It is well known that even accelerated
vaccination schedules donot eliminate theneed for RIG after severe
exposure [5].
Preclinical data have indicated that the CL184 mAb cocktail is
a promising candidate for use as an alternative to HRIG and ERIG
in PEP [9]. In this publication, we present the first clinical data for
CL184.
The local tolerability of CL184was very good, with less than 40%
of subjects in each dosage group reporting pain at the injection site.
In theUS study, some injection site bruisingwas reported.However,
other typical local reactionswere not seen at all. Overall, fewer local
reactionswere observed than in a similar study investigating intra-
muscular administration of HRIG in healthy subjects [15]. Because
of its high concentration, CL184 can be injected in lower volumes
than HRIG or ERIG, which might contribute to better local tolera-
bility. The lower volumes required will also facilitate infiltration of
the complete required dose into the wound, which is critical for
treatment success [7].
Fever was not reported in any subject in either study. General
systemic reactions observed included headache, dizziness, fatigue,
and vomiting. Incidence rates for these symptoms in RAB-M-A001
(USA) were similar or lower than those seen in a US study in
which healthy adults received intramuscular HRIG in combina-
tion with rabies vaccine [15]. In an observational study involving
German healthcare workers, the most frequent adverse events
reported after PEP with HRIG and rabies vaccine were tiredness,
malaise, headache, and dizziness at rates roughly comparable to
those observed in RAB-M-A001 after simulated PEPwith CL184 and
rabies vaccine [16]. Based on the persistence of symptoms during
PEP, the investigators concluded that strong headache, tiredness,
dizziness, and paraesthesia might be symptoms specific to rabies
vaccination. In RAB-M-A001, headache was more frequent after
administration of CL184 alone than after administration in con-
junction with rabies vaccine, although no dose-relationship was
apparent; in RAB-M-A002, only one subject in the CL184 40 IU/mL
group reported headache.
Much lower incidence rates of unsolicited adverse events were
seen in RAB-M-A002 than in RAB-M-A001. This is in line with the
lower rates observed in other studies performed inAsia [17–19] and
canmost likely be attributed to cultural differences in the reporting
of adverse effects.
Routine safety laboratory tests revealedelevationsof clinical rel-
evance inAST,CK-MBor lipase levels.Weassumethat thesefindings
were unspecific, because no other abnormalities indicative of hep-
atic, cardiac, or pancreatic disorders were apparent. CK-MB levels
have been shown to be highly variable in healthy subjects as ele-
vated CK-MB levels can be found; unrelated tomyocardial cause, in
asymptomatic subjects with elevated total CK. In our studies, one
asymptomatic subject had an extremely elevated CK-MB but was
found to have a troponin I level of zero, indicating the absence of
cardiac aetiology.
Administration of recombinant therapeutic proteins, even those
of entirely human origin, could potentially evoke an antibody
response [20]. However, HAHAs specific for CL184 were not
detected in either study. An immune response that could inter-
fere with the activity of the CL184 antibody cocktail is therefore
unlikely.
The efficacy of CL184 administered in PEP can only be fully
demonstrated in patients exposed to rabies andwill depend on the
ability of the mAbs to neutralize rabies virus locally in the wound
[12,21]. In our phase I studies, we measured serum RVNA as a sur-
rogate marker of efficacy. The dose-escalation trials showed a clear
dose response,withpeakRVNA levels in the rangeof thoseobserved
after intramuscular administration of ERIG or HRIG [15,22–24].
Intramuscular administration of HRIG at 20 IU/kg given without
rabies vaccine was reported to result in maximum serum antibody
concentrations around day 3–14 of approximately 0.1 IU/mL with
measurable titers in 56% of the subjects at days 3 and 7 [15]. CL184
administration at 20 IU/kg resulted in similar profiles of neutraliz-
ing activity with detectable levels in 96 and 100% of the subjects at
days 3 and 7 and maximal titers at day 7 of 0.30 IU/mL in RAB-M-
A001 and 0.24 IU/mL in RAB-M-A002, respectively.
When CL184 was administered in conjunction with rabies vac-
cine, all subjects in both studies had RVNA levels considered to be
adequate (>0.5 IU/mL) from day 14 onwards, and these levels were
achieved in 7 of 21 (33%) subjects as early as day 7. If the thresh-
old was set to include levels ≥0.5 IU/mL, as done in studies with
other rabies vaccines than RabAvertTM/RabipurTM, this proportion
is increased to 14 out of 21 (67%) subjects on day 7. These results
are very comparable to those obtained with current PEP regimens
whereby 13–20% of subjects receiving human diploid cell vaccine
(HDCV) plus HRIG seroconverted (≥0.5 IU/mL) at day 7 and 100% of
subjects seroconverted at day 14 [15].
Our studies further confirmed the importance of immediate
administration of RIG to inhibit viral spread during the first 7–14
days, before there is sufficient immune response to the vaccine.
Overall, geometric mean RVNA levels in RAB-M-A002 were lower
than in RAB-M-A001. This might be related to the different levels
of physical activity (the period of confinement without strenuous
activity was longer in RAB-M-A001), slight differences in the vac-
cines that were used (RabAvertTM vs. RabipurTM), or ethnic and
environmental factors.
Results from some previous studies have indicated that RIGs
can potentially interfere with the immune response to rabies vac-
cination [23,25–27]. We did not specifically investigate a potential
interference between CL184 and rabies vaccine in our studies. If
there was any interaction, this was not clinically relevant, as evi-
denced by the high RVNA levels induced by simulated PEP with
CL184 and rabies vaccine.
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In conclusion, our studies confirmed that CL184may offer a safe
and effective alternative for ERIG or HRIG. CL184 is a well-defined
cocktail of two fully human mAbs and can be produced in large
quantities in the extensively characterized and well-established
PER.C6® human cell line. Its successful development would help
to ensure supply of life-saving biologicals to people exposed to
rabies and–coupledwitheducationalmeasures andefforts to elim-
inate canine rabies – could substantially reduce the high death toll
associated with this disease.
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